Selected research
Market Outlook & Growth Opportunities
Global Gadoterate Meglumine Market Outlook and Growth Opportunities 2026
Market perspective
The global Gadoterate Meglumine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Gadoterate Meglumine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gadoterate Meglumine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gadoterate Meglumine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Gadoterate Meglumine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Gadoterate Meglumine market include Hengrui Medicine, Guerbet Group and GE Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Gadoterate Meglumine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gadoterate Meglumine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gadoterate Meglumine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gadoterate Meglumine market size, projected growth trends, production technologies, key applications, and end-use industries.
Gadoterate Meglumine Segment by Company
Hengrui Medicine
Guerbet Group
GE Healthcare
Gadoterate Meglumine Segment by Type
5.6535Gm/15Ml
3.769Gm/10Ml
1.8845Gm/5Ml
Others
Gadoterate Meglumine Segment by Application
Hospitals
Clinics
Gadoterate Meglumine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gadoterate Meglumine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gadoterate Meglumine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gadoterate Meglumine significant trends, drivers, influence factors in global and regions.
6. To analyze Gadoterate Meglumine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gadoterate Meglumine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gadoterate Meglumine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gadoterate Meglumine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gadoterate Meglumine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gadoterate Meglumine industry.
Chapter 3: Detailed analysis of Gadoterate Meglumine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gadoterate Meglumine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gadoterate Meglumine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- 5.6535Gm/15Ml
- 3.769Gm/10Ml
- 1.8845Gm/5Ml
- Others
Applications
- Hospitals
- Clinics
Companies covered
- Hengrui Medicine
- Guerbet Group
- GE Healthcare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Gadoterate Meglumine Sales Value (2021-2032)
- 1.2.2 Global Gadoterate Meglumine Sales Volume (2021-2032)
- 1.2.3 Global Gadoterate Meglumine Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Gadoterate Meglumine Market Dynamics
- 2.1 Gadoterate Meglumine Industry Trends
- 2.2 Gadoterate Meglumine Industry Drivers
- 2.3 Gadoterate Meglumine Industry Opportunities and Challenges
- 2.4 Gadoterate Meglumine Industry Restraints
3 Gadoterate Meglumine Market by Company
- 3.1 Global Gadoterate Meglumine Company Revenue Ranking in 2025
- 3.2 Global Gadoterate Meglumine Revenue by Company (2021-2026)
- 3.3 Global Gadoterate Meglumine Sales Volume by Company (2021-2026)
- 3.4 Global Gadoterate Meglumine Average Price by Company (2021-2026)
- 3.5 Global Gadoterate Meglumine Company Ranking (2024-2026)
- 3.6 Global Gadoterate Meglumine Company Manufacturing Base and Headquarters
- 3.7 Global Gadoterate Meglumine Company Product Type and Application
- 3.8 Global Gadoterate Meglumine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Gadoterate Meglumine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Gadoterate Meglumine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Gadoterate Meglumine Market by Type
- 4.1 Gadoterate Meglumine Type Introduction
- 4.1.1 5.6535Gm/15Ml
- 4.1.2 3.769Gm/10Ml
- 4.1.3 1.8845Gm/5Ml
- 4.1.4 Others
- 4.2 Global Gadoterate Meglumine Sales Volume by Type
- 4.2.1 Global Gadoterate Meglumine Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gadoterate Meglumine Sales Volume by Type (2021-2032)
- 4.2.3 Global Gadoterate Meglumine Sales Volume Share by Type (2021-2032)
- 4.3 Global Gadoterate Meglumine Sales Value by Type
- 4.3.1 Global Gadoterate Meglumine Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Gadoterate Meglumine Sales Value by Type (2021-2032)
- 4.3.3 Global Gadoterate Meglumine Sales Value Share by Type (2021-2032)
5 Gadoterate Meglumine Market by Application
- 5.1 Gadoterate Meglumine Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.2 Global Gadoterate Meglumine Sales Volume by Application
- 5.2.1 Global Gadoterate Meglumine Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gadoterate Meglumine Sales Volume by Application (2021-2032)
- 5.2.3 Global Gadoterate Meglumine Sales Volume Share by Application (2021-2032)
- 5.3 Global Gadoterate Meglumine Sales Value by Application
- 5.3.1 Global Gadoterate Meglumine Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Gadoterate Meglumine Sales Value by Application (2021-2032)
- 5.3.3 Global Gadoterate Meglumine Sales Value Share by Application (2021-2032)
6 Gadoterate Meglumine Regional Sales and Value Analysis
- 6.1 Global Gadoterate Meglumine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gadoterate Meglumine Sales by Region (2021-2032)
- 6.2.1 Global Gadoterate Meglumine Sales by Region: 2021-2026
- 6.2.2 Global Gadoterate Meglumine Sales by Region (2027-2032)
- 6.3 Global Gadoterate Meglumine Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Gadoterate Meglumine Sales Value by Region (2021-2032)
- 6.4.1 Global Gadoterate Meglumine Sales Value by Region: 2021-2026
- 6.4.2 Global Gadoterate Meglumine Sales Value by Region (2027-2032)
- 6.5 Global Gadoterate Meglumine Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Gadoterate Meglumine Sales Value (2021-2032)
- 6.6.2 North America Gadoterate Meglumine Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Gadoterate Meglumine Sales Value (2021-2032)
- 6.7.2 Europe Gadoterate Meglumine Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Gadoterate Meglumine Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Gadoterate Meglumine Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Gadoterate Meglumine Sales Value (2021-2032)
- 6.9.2 South America Gadoterate Meglumine Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Gadoterate Meglumine Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Gadoterate Meglumine Sales Value Share by Country, 2025 VS 2032
7 Gadoterate Meglumine Country-level Sales and Value Analysis
- 7.1 Global Gadoterate Meglumine Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Gadoterate Meglumine Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Gadoterate Meglumine Sales by Country (2021-2032)
- 7.3.1 Global Gadoterate Meglumine Sales by Country (2021-2026)
- 7.3.2 Global Gadoterate Meglumine Sales by Country (2027-2032)
- 7.4 Global Gadoterate Meglumine Sales Value by Country (2021-2032)
- 7.4.1 Global Gadoterate Meglumine Sales Value by Country (2021-2026)
- 7.4.2 Global Gadoterate Meglumine Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.9.2 France Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.16.2 China Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.19.2 India Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Gadoterate Meglumine Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Gadoterate Meglumine Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Gadoterate Meglumine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Hengrui Medicine
- 8.1.1 Hengrui Medicine Company Information
- 8.1.2 Hengrui Medicine Business Overview
- 8.1.3 Hengrui Medicine Gadoterate Meglumine Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Hengrui Medicine Gadoterate Meglumine Product Portfolio
- 8.1.5 Hengrui Medicine Recent Developments
- 8.2 Guerbet Group
- 8.2.1 Guerbet Group Company Information
- 8.2.2 Guerbet Group Business Overview
- 8.2.3 Guerbet Group Gadoterate Meglumine Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Guerbet Group Gadoterate Meglumine Product Portfolio
- 8.2.5 Guerbet Group Recent Developments
- 8.3 GE Healthcare
- 8.3.1 GE Healthcare Company Information
- 8.3.2 GE Healthcare Business Overview
- 8.3.3 GE Healthcare Gadoterate Meglumine Sales, Value and Gross Margin (2021-2026)
- 8.3.4 GE Healthcare Gadoterate Meglumine Product Portfolio
- 8.3.5 GE Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Gadoterate Meglumine Value Chain Analysis
- 9.1.1 Gadoterate Meglumine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gadoterate Meglumine Sales Mode & Process
- 9.2 Gadoterate Meglumine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gadoterate Meglumine Distributors
- 9.2.3 Gadoterate Meglumine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst